Physician profile
Biserka Matkovic
NPI 1972674893
$368.00
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2021: $29.53 · 2023: $85.41 · 2024: $54.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $140.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.18 | 2019 | |
| Janssen Pharmaceuticals, INC | $49.79 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $32.87 | 2019 | |
| Dynavax Technologies Corporation | $31.77 | 2023 | Heplisav-B |
| Angiodynamics, INC. | $29.53 | 2021 | |
| Abbvie INC. | $27.43 | 2024 | |
| Emd Serono, INC. | $27.22 | 2024 | |
| Sanofi-Aventis U.S. LLC | $24.30 | 2019 | |
| Atricure, INC. | $19.39 | 2023 | |
| Pulmonx Corporation | $19.19 | 2023 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Pfizer INC. | $15.90 | 2019 | |
| Glaxosmithkline, LLC. | $15.06 | 2023 | Shingrix |
| Merck Sharp & Dohme LLC | $14.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Biserka Matkovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.